However, Aurora-A overexpression is observed in numerous cancer types irrespective of cell cycle phases.286 In cancer cells, Aurora-A suppresses apoptosis and autophagy, activates the Wnt/β-catenin signaling pathway and promotes EMT.287 Of note, Aurora-A inhibition is synthetic lethal with tumor suppressor gene deficiencies such as RB1, SNF5, SMARCA4 or ARIDA1A.286 Interestingly, Aurora-A is also associated with resistance to EGFR288 or PI3K-mTOR-Akt289 pathway inhibitors, and the addition of Aurora-A inhibitors can circumvent the resistance in preclinical studies. The gene discussed is SMARCA4; the disease is cancer.